The emergence of SARS-CoV-2 variants has raised concerns about altered sensitivity to
antibody-mediated immunity. The relative resistance of SARS-CoV-2 variants B. 1.1. 7 and …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to
emerge during the global pandemic and may facilitate escape from current antibody …

Terminating the SARS-CoV-2 pandemic relies upon pan-global vaccination. Current
vaccines elicit neutralizing antibody responses to the virus spike derived from early isolates …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

Severe acute respiratory syndrome coronavirus 2 variants have continued to emerge in
diverse geographic locations with a temporal distribution. The Lambda variant containing …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

Background Mutations accrued by SARS-CoV-2 lineage P. 1—first detected in Brazil in early
January, 2021—include amino acid changes in the receptor-binding domain of the viral …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B. 1.1. 7 and B. 1.351
variants were first identified in the United Kingdom and South Africa, respectively, and have …